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ACall to Action in the Post-Coronary Artery Bypass Graft Patient*John S. Douglas, JR, MDP atients who have previously undergone coro-nary revascularization bring a variable degreeof added complexity to the delivery of timely
reperfusion in ST-segment elevation myocardial
infarction (STEMI). Patients with previous revascula-
rization are more likely to be elderly and to have
comorbidities that blunt the symptomatic presenta-
tion of ischemia and its recognition and to be at
increased risk. Knowledge of abnormal baseline
electrocardiograms and details of previous revascular-
ization are frequently absent in previously revascular-
ized patients, and diagnostic procedures are often
more lengthy. Arterial access options may be limited
by peripheral vascular disease and other patient-
speciﬁc factors. Delays to reperfusion (increased
ischemic time) translate into increased infarct size
and mortality. Recent studies in which the time of
onset of myocardial infarction was measured objec-
tively by backward extrapolation of troponin curves
suggested that the biological onset of ischemia and
infarction was substantially earlier than the patient-
recognized symptom onset and that the differences
were more pronounced in older patients and those
with more complexity (1). Interestingly, and perhaps
not surprisingly, patients having undergone a previ-
ous percutaneous coronary intervention (PCI) were
more likely to recognize the onset of ischemia, which
may lead to better outcomes in these patients.
Current guideline statements do not provide spe-
ciﬁc recommendations for STEMI patients with*Editorials published in the JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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relevant to the contents of this paper to disclose.previous surgical revascularization, a patient sub-
group with a number of issues not encountered in
nonsurgical patients, including the need to treat
bypass grafts. In the APEX-AMI (Assessment of
PEXelizamab in Acute Myocardial Infarction) trial of
128 post-coronary artery bypass graft (CABG) patients,
63 (41%) had saphenous vein graft (SVG) culprit
vessels, and the 90-daymortality ratewas signiﬁcantly
increased in SVG-treated patients (19% vs. 5.7%;
p ¼ 0.05) (2). Similarly, in 192 post-CABG patients who
underwent primary PCI, Gaglia et al. (3) reported a
signiﬁcantly higher 30-day mortality rate in patients
with SVG compared with native vessel PCI (14.3% vs.
8.4%; p ¼ 0.03). In a more recent single-center, retro-
spective study, Kohl et al. (4) reported that 249 of 3,542
consecutive STEMI patients (7%) had a previous CABG,
that the culprit vessel was an SVG in 34%, a native
vessel in 42%, and no clear culprit in 24%. Despite
higher comorbidity, patientswith a previous CABGhad
a similar mortality rate compared with those without a
previous CABG in-hospital (4.8% vs. 5.2%; p ¼ 0.82)
and at 1 year (10.8% vs. 9.1%; p ¼ 0.36). The mortality
rate was numerically higher (but not statistically) with
an SVG PCI compared with a native vessel PCI at 30
days (8.3% vs. 3.9%; p ¼ 0.19) and at 1 year (14.3% vs.
9.0%; p ¼ 0.35). The American College of Cardiology/
American Heart Association Task Force on Practice
Guidelines (Committee on Management of Acute
Myocardial Infarction) classiﬁed a PCI of an SVG as
Class IIa, “acceptable, of uncertain efﬁcacy andmay be
controversial; weight of evidence in favor of useful-
ness/efﬁcacy” (5).SEE PAGE 1954In this issue of JACC: Cardiovascular Interven-
tions, Gruberg et al. (6) report from the National
Cardiovascular Data Registry (NCDR) in-hospital
outcomes of 15,628 STEMI patients treated from
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19642009 through 2011 in 297 U.S. hospitals comparing
patients with previous revascularization (CABG or
PCI) to those without previous revascularization.
They excluded patients with shock, cardiac arrest,
and between-hospital transfers. Patients with previ-
ous surgical revascularization were signiﬁcantly older
than those with a previous PCI or no previous revas-
cularization (66 vs. 60 vs. 59 years; p ¼ 0.001) and had
signiﬁcantly more diabetes, peripheral vascular dis-
ease, dyslipidemia, heart failure, previous myocardial
infarction, and long-term dialysis. The unadjusted
mortality rate of post-CABG patients was signiﬁcantly
higher than that of patients with no previous revas-
cularization (3.3% vs. 1.8%; p ¼ 0.0089), with a
numerically higher mortality rate in patients with
culprit lesions in a graft (4.3% vs. 1.8%; p ¼ 0.065).
Unadjusted major adverse cardiac and cerebrovascu-
lar events and major bleeding were similar in the
3 groups of patients.
There were signiﬁcant between-group differences
in angiographic and procedural characteristics.
Lesion complexity was greater in post-CABG patients,
and left ventricular function was poorer. The culprit
vessel was the left anterior descending coronary ar-
tery in w40% of patients with a previous PCI or no
previous revascularization and in only 14.5% of post-
CABG patients. In previous CABG patients, the target
vessel was the right coronary artery in 56% of pa-
tients. These ﬁndings suggest that less myocardium
was at risk in post-CABG patients, which may have
offset to a degree the advanced age and comorbidity
of post-CABG patients. An important and potentially
modiﬁable factor in post-CABG patients was the lower
percentage of patients achieving door-to-balloon
time #90 min compared with patients with a previ-
ous PCI or no previous revascularization (76.4% vs.
88.5% vs. 88%). A door-to-balloon time #90 min was
achieved in 90.1% of previous PCI patients with in-
stent restenosis, but in only 75.9% when the culprit
lesion was in a bypass graft. This delay to reperfusion
has important implications for myocardial salvage.
However, door-to-cath lab and cath lab-to-balloon
times were not provided, so it is not clear where
the delay occurred. Increased awareness of “time
is muscle” may lead to shortened door-to-cath lab
times, and timely performance of the more complex
diagnostic study in post-CABG patients may shorten
cath lab-to-balloon times in these patients. It is
noteworthy that, at Abbott Northwestern Hospital, a
center with a special focus on primary PCI, door-to-
balloon times for post-CABG patients were not
different from those of patients without previous
surgery and that in-hospital and 1-year mortality rates
were similar (4).In the patients with a previous CABG in this NCDR
report, 54.4% underwent PCI of a graft lesion, and
there was a trend among these patients for increased
unadjusted and adjusted mortality compared with
native vessel PCI. The frequency of use of embolic
protection devices (EPDs) was not stated. There has
been no dedicated trial to evaluate their use in STEMI
with an SVG culprit vessel, and results of studies in
native vessels have not been encouraging. In a recent
report from theNCDR for the 2005 to 2009 period, EPDs
were used in only 21% of SVG PCIs and even less
frequently in STEMIs (7). Given the complexity of the
infarct vessel with increased thrombus burden,
impaired visualization of the distal vessel and the need
to cross the culprit lesion with a bulky ﬁlter, it seems
unlikely that more frequent use of EPDs would have a
positive impact on outcomes. In the observational
NCDR report by Brennan et al. (7), use of EPDs was
associated with a slightly higher risk of procedural
complications, calling into question the value of
routine use of EPDs. The increased cost and complexity
of EPDs and potential complications have negatively
affected their use in contemporary SVG PCI where
direct stenting, conservative stent sizing, and avoid-
ance of post-deployment balloon dilation yield a low
rate of periprocedural myocardial infarction and no
reﬂow in selected patients without bulky SVG target
lesions. Notably, in the ISAR-CABG (Intracoronary
Stenting and Antithrombotic Research-CABG) study,
in which 610 patients underwent stent implantation in
SVGs, the occurrence rate of major adverse cardiac
events at 30 days was only 4% despite the use of EPDs
in <5% of patients (8). It seems clear that practice
patterns inplace at the time that the SAFER (Saphenous
vein graft Angioplasty Free of Emboli Randomized)
trial was conducted were quite different from those
used today. In the SAFER trial, which is the only
randomized trial in which embolic protection was
compared with no embolic protection, further balloon
dilation after stent deployment, a practice usually
avoided currently, was used in 40% of control
patients and 27% of EPD-treated patients (9). Perhaps
of even more signiﬁcance, the balloon size used was
larger than the reference vessel diameter (4.2 mm vs.
3.4 mm). Post-dilation with a large balloon, which was
performed more in the control group, may have
increased periprocedural myocardial infarction.
Perhaps the most important take-home message
from the work of Gruberg et al. (6) is that patients
with a previous CABG presenting to NCDR hospitals
with STEMI experienced delays to reperfusion
compared with other patients and had a higher
unadjusted rate of in-hospital major adverse cardiac
and cerebrovascular events. This contrasts with the
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1965experience reported by Kohl et al. (4), who, by using
standardized protocols in a regional STEMI system,
were able to achieve equally prompt reperfusion and
similar outcomes in post-CABG patients compared
with other STEMI patients. The observations of
Gruberg et al. (6) should be interpreted as a “call to
action,” with the goal of earliest possible reperfusionin all patients with STEMI, including those who have
had a previous CABG.
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